Optimal use recommendations for second- and third-line therapy for patients with type 2 diabetes
Evidence-informed recommendations were developed by the Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. What is the optimal second-line therapy for patients with type 2 diabetes experiencing inadequate glycemic control with metformin monotherapy? 2. What is the op...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2013, July 2013
|
| Series: | CADTH optimal use report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Evidence-informed recommendations were developed by the Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. What is the optimal second-line therapy for patients with type 2 diabetes experiencing inadequate glycemic control with metformin monotherapy? 2. What is the optimal third-line therapy for patients with type 2 diabetes experiencing inadequate glycemic control with metformin and a sulfonylurea? 3. If insulin continues to be the recommended third-line therapy for most patients, what alternative(s) are recommended for patients unable to use insulin? 4. What is the role, if any, for the combined use of insulins and incretin agents in patients with type 2 diabetes? |
|---|---|
| Physical Description: | 1 PDF file (ii, 19 pages) |